Advisor Group Holdings, Inc. Humanigen, Inc Transaction History

Advisor Group Holdings, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.15 - $3.02 $300 - $6,040	-2,000 Reduced 14.34%	11,950 $2,000
Q2 2022 Aug 10, 2022	SELL	$1.76 - $3.33 $1,038 - $1,964	-590 Reduced 4.06%	13,950 $25,000
Q1 2022 May 04, 2022	BUY	$1.81 - $3.97 $1,158 - $2,540	640 Added 4.6%	14,540 $44,000
Q3 2021 Nov 05, 2021	BUY	$5.93 - $17.83 $36,914 - $110,991	6,225 Added 81.11%	13,900 $83,000
Q2 2021 Aug 02, 2021	BUY	$13.54 - $22.74 $68,377 - $114,836	5,050 Added 192.38%	7,675 $134,000
Q1 2021 May 13, 2021	BUY	$12.91 - $23.83 $30,015 - $55,404	2,325 Added 775.0%	2,625 $50,000
Q4 2020 Feb 10, 2021	SELL	$7.97 - $21.66 $2,391 - $6,498	-300 Reduced 50.0%	300 $5,000
Q3 2020 Nov 12, 2020	BUY	$8.0 - $28.5 $4,800 - $17,100	600 New	600 $6,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.